4. The Changing Field of Melanoma: Ipilimumab

5. The Changing Field of Melanoma: BRAF Mutations

6. The Changing Field of Melanoma: PD-1 and PD-L1 Antibodies

7. Preferred Regimens for Metastatic Melanoma

8. Considerations With the New Agents

9. First-Line Therapy for Patients With BRAF Mutation

10. First-Line Therapy for Patients With BRAF Wild Type

11. Immune-Related Response Criteria

12. Investigational PD-1 Inhibitors

13. Investigational Combination Therapy

14. Questions to Be Answered About PD-1-Blocking Antibodies

15. Other Investigational Approaches

16. Other Investigational Approaches (cont)

17. Investigational Combination Approaches

18. Abbreviations

19. Abbreviations (cont)

20. References

21. References (cont)

22. References (cont)

23. References (cont)

24. References (cont)